DM3

General Information


DRACP ID  DRACP00544

Peptide Name   DM3

Sequence  GLFDIWKWWRWRR

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=56.0±9.3µg/ml CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay 24h 1

Hemolytic Activity  Human erythrocytes:10% Hemolysis=52.7±5.5µg/ml; 50% Hemolysis>250µg/ml

Normal (non-cancerous) Cytotoxicity  NL20: 50% Cell death=68.5±11.0µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00544

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C95H129N27O16

Absent amino acids  ACEHMNPQSTVY

Common amino acids  W

Mass  211946

Pl  12.22

Basic residues  4

Acidic residues  1

Hydrophobic residues  7

Net charge  3

Boman Index  -3595

Hydrophobicity  -106.15

Aliphatic Index  60

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  22000

Absorbance 280nm  1833.33

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25985150

Title  In vitro properties of designed antimicrobial peptides that exhibit potent antipneumococcal activity and produces synergism in combination with penicillin

Doi 10.1038/srep09761

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.